QIAGEN N.V.

QGEN Healthcare Diagnostics & Research

QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 7.94%, free cash flow grew 30.5% and total debt rose 13.8%, each against the same quarter a year earlier.

46.13 0.04 −0.09%
Market cap
$9.5B
P/E
23.6×
Fwd P/E
17.5×
Dividend yield
0.76%
F-score
8/9
Altman Z
3.81
Beneish M
−2.60
Dividend safety
66/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
20.03 20.91 22.30 23.07

+8 more quarters

P/S ratio
3.84 3.95 4.67 4.45
P/FCF ratio
18.31 20.52 21.84 19.48
P/Operating CF
40.20 82.37 51.92 55.78
P/B ratio
2.40 2.49 2.59 2.52
EV/Sales
4.25 4.66 5.18 4.66
EV/EBITDA
13.70 15.31 16.33 14.16
EV/FCF
20.24 24.24 24.20 20.41
Current Ratio
2.85 3.21 3.90 2.60
Net Debt/EBITDA
4.63 7.34 3.71 2.41
Debt/Equity
0.49 0.49 0.44 0.58
Earnings Yield
4.99% 4.78% 4.48% 4.34%
Free Cash Flow Yield
5.46% 4.87% 4.58% 5.13%
Free Cash Flow per Share
0.76 0.25 0.54 0.56
Book value per Share
16.27 16.09 17.39 17.71
Free Cash Flow
157.32 52.15 116.55 114.57
EV/EBIT
20.02 22.51 23.23 19.86
Other line items

Show all line items

Columns are period end dates